Two Eras of Weight Loss Pharmacology
Phentermine has been approved for weight loss in the United States since 1959. It is a sympathomimetic amine that suppresses appetite by increasing norepinephrine levels in the brain. It is cheap, effective for short-term use, and widely prescribed. Retatrutide, still in clinical trials, represents the opposite end of the pharmacological spectrum: a designer peptide targeting three specific metabolic receptors. The two drugs share the goal of weight loss but achieve it through completely different mechanisms with different safety profiles, durations of use, and efficacy. This comparison puts them side by side.
Efficacy Comparison
Phentermine produces average weight loss of 3-7% of body weight over 12 weeks of use. It is approved only for short-term use — typically 12 weeks or less — because tolerance develops and the drug becomes less effective over time. Retatrutide produces 28.3% average weight loss over 80 weeks, based on the TRIUMPH-1 trial results announced in May 2026. The difference in both magnitude and duration is substantial. Phentermine is a starter drug for people who need modest, short-term weight loss support. Retatrutide is a comprehensive metabolic intervention that produces sustained, large-magnitude weight loss.
Safety and Side Effects
Phentermine increases heart rate and blood pressure as a direct effect of its sympathomimetic mechanism. It can cause insomnia, dry mouth, constipation, and anxiety. The drug carries a black box warning for cardiovascular disease and is contraindicated in patients with hypertension, hyperthyroidism, or a history of drug abuse. Retatrutide also increases heart rate by 2-5 bpm but through a different mechanism — glucagon receptor activation rather than sympathetic nervous system stimulation. The side effect profiles of the two drugs are different enough that one may be safer for a particular individual than the other, depending on their health history.
Leave a Reply